PAX3 and alveolar rhabdomyosarcoma: Patients diagnosed with PAX3-FOXO1-positive ARMS have a 4-year survival rate of 8%.12 This poor prognosis stems in part from these tumor cells having a higher incidence of localized invasion,12 which may then lead to heightened aggressiveness and an increased propensity for metastasis.